Abstract
Snakebite is a medical emergency in many parts of the world, particularly in the temperate regions. According to 2007 World Health Organization (WHO) report, there are about 5 million snakebite incidences resulting in 2.5 million envenoming, and 125,000 deaths occur annually. Most affected are the healthy individuals like children and farming populations with resource poor settings and away from health care centers in low-income countries of Africa, Asia and Latin America. In view of this, the WHO has declared snakebite as an ignored health crisis and a tropical disease. Although the death rate has reduced markedly due to anti-venom regiment, several limitations of it offer scope for better understanding of various ignored issues. Currently, snakebite therapeutics facing plethora of scientific, technological and public health challenges, including secondary/long term complications that have not been given importance so far. Because of dearth of knowledge, venom researchers and medical practitioners from affected countries worldwide should join together to accomplish this scenario. In view of this, the present review provides a broader perspective on the possible production and application of highly effective therapeutic master anti-venom, designing master diagnostic kit and also to deal with the inefficacy of anti-venom therapy against local manifestations and secondary complications of snakebite. The review demands thorough understanding of venom pharmacology, inculcating new strategies to handle and to enhance the efficacy of snakebite management and urge the governing systems of affected countries to take steps to curtail accidental debilitation and death rate of healthy individuals due to snakebite.
Keywords: Snake venom, local effects, SVMPs, antivenom, hyaluronidase, ECM, Snakebite, therapeutic master anti-venom, inefficacy of anti-venom therapy, tropical disease
Current Topics in Medicinal Chemistry
Title: Overlooked Issues of Snakebite Management: Time for Strategic Approach
Volume: 11 Issue: 20
Author(s): K. S. Girish and K. Kemparaju
Affiliation:
Keywords: Snake venom, local effects, SVMPs, antivenom, hyaluronidase, ECM, Snakebite, therapeutic master anti-venom, inefficacy of anti-venom therapy, tropical disease
Abstract: Snakebite is a medical emergency in many parts of the world, particularly in the temperate regions. According to 2007 World Health Organization (WHO) report, there are about 5 million snakebite incidences resulting in 2.5 million envenoming, and 125,000 deaths occur annually. Most affected are the healthy individuals like children and farming populations with resource poor settings and away from health care centers in low-income countries of Africa, Asia and Latin America. In view of this, the WHO has declared snakebite as an ignored health crisis and a tropical disease. Although the death rate has reduced markedly due to anti-venom regiment, several limitations of it offer scope for better understanding of various ignored issues. Currently, snakebite therapeutics facing plethora of scientific, technological and public health challenges, including secondary/long term complications that have not been given importance so far. Because of dearth of knowledge, venom researchers and medical practitioners from affected countries worldwide should join together to accomplish this scenario. In view of this, the present review provides a broader perspective on the possible production and application of highly effective therapeutic master anti-venom, designing master diagnostic kit and also to deal with the inefficacy of anti-venom therapy against local manifestations and secondary complications of snakebite. The review demands thorough understanding of venom pharmacology, inculcating new strategies to handle and to enhance the efficacy of snakebite management and urge the governing systems of affected countries to take steps to curtail accidental debilitation and death rate of healthy individuals due to snakebite.
Export Options
About this article
Cite this article as:
S. Girish K. and Kemparaju K., Overlooked Issues of Snakebite Management: Time for Strategic Approach, Current Topics in Medicinal Chemistry 2011; 11 (20) . https://dx.doi.org/10.2174/156802611797633393
DOI https://dx.doi.org/10.2174/156802611797633393 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Nutraceuticals - An Emerging Era in the Treatment and Prevention of Cardiovascular Diseases
Current Pharmaceutical Biotechnology Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design Pharmacogenomics in Aspirin Intolerance
Current Drug Metabolism Antihistamine Use in Dermatologic Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Management of Food-Induced Anaphylaxis: Unsolved Challenges
Current Clinical Pharmacology The Use of N-Acetylcysteine in Respiratory Diseases
Current Respiratory Medicine Reviews Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Genetic Engineering of Allergens for Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Novel Drugs for Inflammatory Lung Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Hypersensitivity Reactions to Non-Steroidal Anti-Inflammatory Drugs
Current Drug Metabolism Monoclonal Antibodies in Allergy; Updated Applications and Promising Trials
Recent Patents on Inflammation & Allergy Drug Discovery Reporting Rates of Yellow Fever Vaccine 17D or 17DD-Associated Serious Adverse Events in Pharmacovigilance Data Bases: Systematic Review
Current Drug Safety Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Review on Plants with Traditional Uses and Bio-activity against Hair Graying
Current Traditional Medicine Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner?
Current Drug Targets Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Characteristics of Asian Mosquito Saliva Allergens for Specific Diagnoses and Effective Therapies
Current Protein & Peptide Science